Dr. Gaba is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham and Women's Hospital
Boston, MA 02115
Summary
- Brigham and Women's Hospital Cardiology Fellow
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2020
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2018 - 2020- New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 2017 - 2018
Mayo Clinic College of MedicineClass of 2017
California Institute of Technology (Caltech)BS, 2009 - 2013
Certifications & Licensure
MA State Medical License 2020 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 1 citationsIntraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial.Prakriti Gaba, Robert S Rosenson, J Antonio G López, Gerald F Watts, Thorsten M Leucker
Journal of the American College of Cardiology. 2025-02-11 - 3 citationsPercutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis...Prakriti Gaba, Joseph F Sabik, Sabina A Murphy, Andrea Bellavia, Patrick T O'Gara
Circulation. 2024-04-23 - 2 citationsIcosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.Prakriti Gaba, Deepak L Bhatt, William E Boden
European Heart Journal. 2024-02-07
Press Mentions
Lp(A) Can Vary over Time in ASCVD Patients with High Baseline Levels: OCEAN(a)-DOSEDecember 13th, 2024- Icosapent Ethyl’s CV Mortality Benefit Magnified in Patients with Prior MIApril 25th, 2022
- Icosapent Ethyl’s CV Mortality Benefit Magnified in Patients with Prior MIApril 25th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
